Dicerna Pharmaceuticals, Inc. (DRNA) shares are surging on Thursday morning trade after the company as it has signed a definitive agreement to be acquired by Novo Nordisk for $3.3 billion or $38.25 per share in cash. The transaction, expected to close in the fourth quarter of 2021, was unanimously approved by the Dicerna and Novo Nordisk boards
.
The acquisition of Dicerna is expected to accelerate Novo Nordisk's research within RNAi and expand the usage of the RNAi technology. It will combine Dicerna's state-of-the-art RNAi drug engine and intracellular delivery with Novo Nordisk's capabilities in disease biology understanding and tissue targeting through peptides and proteins.
Currently Dicerna shares are trading at $37.94, up 78.29 percent from the previous close of $21.28 on a volume of 12,136,761. For the 52-week period, the shares have traded in a range of $19.06-$40.14 on average volume of 796,087.
For comments and feedback: editorial@rttnews.com